Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Chief Financial Officer | July 17, 2026 | July 21, 2026 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Chief Financial Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date July 17, 2026 · Filed July 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2036-07-16 | Direct | 2,000,000 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Grant · Acquired 2,000,000 · Balance 2,000,000 F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 29, 2027; and 1/48th of the shares subject to the option vest monthly thereafter over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Company's 2026 Inducement Plan) through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 29, 2027; and 1/48th of the shares subject to the option vest monthly thereafter over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Company's 2026 Inducement Plan) through each such vesting date.
Tempest Therapeutics, Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2036-03-30 | Direct | 140,000 |
Reported balance
After 2026-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 140,000 · Balance 140,000 F1: This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2026 Filed Jul 21, 2026 20:51 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 2,000,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001871423-26-000010 · ownership.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Class A Common Stock · 2,000,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 29, 2027; and 1/48th of the shares subject to the option vest monthly thereafter over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Company's 2026 Inducement Plan) through each such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:00 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001871423-26-000002 · form4-04022026_050421.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-03-30 F1 · derivative.exercise_date: This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:00 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001415889-25-000805 · form4-01062025_050112.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:38 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001209191-24-001035 · doc4.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service. Read SEC document |
| October 11, 2023 Filed Oct 13, 2023 20:38 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.77 | $0.00 |
DisclosureSEC source: 0001209191-23-052780 · doc4.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-10-10 F1 · derivative.exercise_date: 25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:59 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 38,425 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002142 · doc4.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,425 Underlying: Common Stock · 38,425 shares Expires 2033-01-02 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 20:35 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 51,270 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001179110-22-003401 · edgar.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,270 Underlying: Common Stock · 51,270 shares Expires 2032-06-20 F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 00:26 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001209191-22-002251 · doc4.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2032-01-03 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:27 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 23,225 | $0.00 Strike: $24.19 | $0.00 |
DisclosureSEC source: 0001567619-21-013380 · doc1.xml · derivative · entry 1 Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,225 Underlying: Common Stock · 23,225 shares Expires 2031-07-11 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on July 12, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.